Ependymoma recurrent
Clinical trials for Ependymoma recurrent explained in plain language.
Never miss a new study
Get alerted when new Ependymoma recurrent trials appear
Sign up with your email to follow new studies for Ependymoma recurrent, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo therapy offers hope for kids with hard-to-treat brain cancers
Disease control Recruiting nowThis study tests a combination of drugs given in low, frequent doses to slow or stop the growth of recurrent brain tumors in children. The goal is to extend survival while maintaining quality of life. About 232 children with medulloblastoma, ependymoma, ATRT, or other rare CNS tu…
Matched conditions: EPENDYMOMA RECURRENT
Phase 2 • Sponsor: Medical University of Vienna • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Sound waves open brain barrier to deliver cancer drug in kids
Disease control Recruiting nowThis early-stage trial tests whether using focused ultrasound with microbubbles can temporarily open the blood-brain barrier, allowing the immunotherapy drug nivolumab to reach brain tumors more effectively. It includes 30 children and young adults with relapsed diffuse midline g…
Matched conditions: EPENDYMOMA RECURRENT
Phase 1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Promising combo targets Hard-to-Treat childhood cancers
Disease control Recruiting nowThis study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…
Matched conditions: EPENDYMOMA RECURRENT
Phase 1/2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for kids with tough brain tumors: gene therapy meets immunotherapy and radiation
Disease control Recruiting nowThis early-phase trial is testing a combination of three treatments for children whose brain tumors have come back or not responded to standard care. The experimental drug SGT-53 delivers a normal TP53 gene to tumor cells, and is given alongside the immunotherapy Nivolumab and ra…
Matched conditions: EPENDYMOMA RECURRENT
Early phase 1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC